IMMUPHARMA PLC — Major Shareholding Notification 2016

Dec 29, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9563S

Immupharma PLC

29 December 2016

RNS : FOR IMMEDIATE RELEASE	29 DECEMBER 2016

ImmuPharma PLC

("ImmuPharma" or the "Company")

TR1 NOTIFICATION OF MAJOR INTEREST

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capital LP ("Lanstead"). Lanstead's holding in ImmuPharma is now confirmed at a total of 7,421,555 Ordinary Shares which equates to a current position in the Company of 5.95% of the 124,638,362 total voting rights.

Full disclosure of the TR1 is shown below:

-Ends-

For further information please contact:

ImmuPharma plc (www.immupharma.org)	+ 44 (0) 20 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma	+ 44 (0) 7721 413496
Panmure, Gordon & Co., (NOMAD & Broker)	+44 (0) 20 7886 2500
Freddy Crossley, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking Northland Capital Partners Limited (Joint Broker) Patrick Claridge, David Hignell, Corporate Finance Rob Rees, John Howes, Corporate Broking	+44 (0)20 3861 6631

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii			Immupharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				x
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other	(please specify):
3. Full name of person(s) subject to the notification obligation: iii		Lanstead Capital LP
4. Full name of shareholder(s) (if different from 3.):iv
5. Date of the transaction and date on which the threshold is crossed or reached: v		28 December 2016
6. Date on which issuer notified:		28 December 2016
7. Threshold(s) that is/are crossed or reached: vi, vii		8%, 7%, 6%

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction						Resulting situation after the triggering transaction
Number of Shares			Number of Voting Rights			Number of shares		Number of voting rights			% of  voting rights x
Direct		Direct xi		Indirect xii	Direct			Indirect
GB0033711010	10,521,555			10,521,555			7,421,555		7,421,555			5.95%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument			Expiration date xiii		Exercise/ Conversion Period xiv					Number of voting rights that may be acquired if the instrument is exercised/ converted.				% of voting rights
N/A
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument		Exercise price		Expiration date xvii		Exercise/ Conversion period xviii			Number of voting rights instrument refers to				% of voting rights xix, xx
N/A													Nominal			Delta
Total (A+B+C)
Number of voting rights								Percentage of voting rights
7,421,555								5.95%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
N/A
Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:
14. Contact name:	Lisa De Vargas, Lanstead Partners Limited
15. Contact telephone number:	+1 (801) 895-3700

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLBKLFLQLFEFBL